# Emkay Research

29 January 2008

### Buy

Price	Target Price
Rs 37	Rs54

Sensex - 18153

#### **Price Performance**

(%)	1M	3M	6M	12M
Absolute	(27)	(8)	(1)	(23)
Rel. to Sensex	(19)	(3)	(16)	(39)

Source: Bloomberg

#### **Stock Details**

Automobiles
ASOK.BO
AL@IN
1330
1
58/26
49
18243520
) 21.9

### Shareholding Pattern (%)

(30th Sep.'07)

Promoters	51.0
FII/NRI	17.2
Institutions	15.9
Private Corp.	3.4
Public	12.5

### **Chirag Shah**

chirag.shah@emkayshare.com

+91 22 6612 1252

# Ashok Leyland Itd.

### In line with expectations...

Ashok Leyland reported its 3QFY08 numbers. Volumes declined by 5.5% Yoy to 18965 units. However, net sales grew by 1.3% YoY to Rs 18 bn backed by spare parts and defence sales and approximately 4% pricing action during preceding 12 months. However, EBIDTA has registered a declined by 10% YoY to Rs 1.7 bn. This is largely due to significant increase in the employee cost, which increased by 29% YoY on account of employee addition as well as wage revisions. Infact, increase in wage costs overshadowed the efforts of the company on the raw material ans well as other expenses front. Higher depreciation charge and rising interest costs resulted in adjusted net profits to decline by 17.5% YoY to Rs 916 mn.

The results were in line with our expectations. We have adjusted our estimates to factor in aggressive employee addition and better than expected productivity improvement. Also, we have introduced FY10 estimates. At Rs 37, the stock trades at PER of 9.3 times and 8.3 times our FY09 and FY10 EPS of Rs 4 and 4.5 respectively. Post the recent correction in the stock price, we believe that the valuations have turned attractive. We upgrade our recommendation from *HOLD to BUY*.

### Spare parts and defense business drives the growth

Despite a decline of 5.5% YoY in volumes to 18965, the revenues increased by 1.3% YoY to Rs 18 bn The growth can be attributed to pricing action (approx 4%) undertaken by the company during the preceding 12 months and higher spare parts and defense sales. Infact, the spare parts and defense sales, increased by 13% YoY to Rs 2 bn. Also higher sales of passenger carriers compensated for decline sales of high tonnage goods vehicles (> 16 Tonnes). Average realization improved by 6% YoY to Rs 843175.

Product mix %	3QFY08	3QFY07	2QFY08
Goods Carriers			_
upto 16 t	28.2	24.1	29.3
> 16 t	71.8	75.9	70.7
Total	100.0	100.0	100.0
Passenger Carriers	27.4	22.3	35.7
Goods Carriers	72.6	77.7	64.3
Total	100.0	100.0	100.0

## Rise in employee costs overshadows the results of productivity and efficiency gains

EBIDTA declined by 10% YoY to 1.7 bn. EBIDTA margins declined by 110 bps YoY to 9.4%. The fall in EBIDTA margins is largely attributable to significant increase in the staff costs, which increased by 29% YoY to Rs 1.5 bn (as a % of sales, staff cost increased by 170 bps YoY to 8.2%). There has been an employee addition to the tune of 600 people (largely in the executive category) for the existing operations as well as greenfield expansion plan at Uttarkhand. Also, there has been wage revision during 4QFY07. Having said that, the benefits of productivity improving program (Mission Gemba), appears to start yielding results as is evident from the control on raw material as well as other expenses.

### One time income props up the bottom-line

During the quarter, the company further reduced its stake in IndusInd bank by 1% to 8.94%, resuting in a gain of Rs 330 mn. As a result, the net profits grew by 14% YoY to 1.2 bn. However, adjusting for this income the net profits have declined by 17.5% YoY to Rs 916 mn, which is 3% lower than our estimates, primarily due to higher staff expenses.

### **Introducing FY10 numbers**

We have introduced our FY10 estimates. On the industry front we expect the domestic M&HCV industry to grow by 6.7% YoY to 328,000 units and exports to grow by 12.5% YoY to 31,400 units. Overall, we have factored in 7.2% YoY growth in the M&HCV industry to 359,400 units.

For Ashok Leyland, we expect the to report 8.2% YoY growth to 96800 units in domestic market and 20% growth in exports to 9500 units. We expect the company to improve its market share from 28.3% in FY08 to 29.5% in FY10 in the domestic market.

We believe that there is a high probability of out-performance in the bus segment, considering the fact that the company has a strong presence amongst STUs and there is an expectation of steady demand from STUs in Andra Pradesh, Tamil Nadu, Karnataka, Haryana and UP.

### **Valuation and View**

We have been conservative in our volume forecast estimates considering the potential triggers that exist for the M&HCV segment with respect to stringent implementation of overloading ban as well as implementation of BS III norms in 2010 and the underlying strength of the Indian economy. Also, we would like to highlight the fact that going ahead, the volume growth may not be right indicators of the actual growth due significant rise in the demand for higher tonnage vehicles. Having said that, we would prefer to witness the turnaround before factoring in higher volume/tonnage growth

At Rs 37, the stock trades at PER of 9.3 times and 8.3 times our FY09 and FY10 EPS of Rs 4 and 4.5 respectively. Post the recent correction in the stock price, we believe that the valuations have turned attractive. We upgrade our recommendation from **HOLD** to **BUY**.

Rs mn	3QFY07	3QFY08	% change	9MFY07	9MFY08	% change
Net Sales	17,776	18,001	1.3	48.772	51.671	5.9
Operating Expenses	17,770	10,001	1.0	40,772	01,071	0.0
Raw Materials	13,554	13,590	0.3	37,225	38,730	4.0
% of Sales	76.2	75.5	0.5	76.3	75.0	4.0
Staff Costs	1,149	1,478	28.6	3,644	4,488	23.2
% of Sales	6.5	8.2	20.0	7.5	8.7	20.2
	1,205	1,245	3.4	3,501	3,581	2.3
Other Expenses	•	•	3.4	•	•	2.3
% of Sales	6.8	6.9	0.7	7.2	6.9	40.7
EBIDTA	1,869	1,687	-9.7	4,402	4,872	10.7
EBIDTA %	10.5	9.4		9.0	9.4	
Depreciation	332	408	22.9	1,024	1,287	25.7
EBIT	1,536	1,279	-16.8	3,377	3,584	6.1
Other Income	64	107	68.5	309	294	-4.9
Interest	26	152	494.5	35	406	1,076.7
PBT	1,574	1,233	-21.7	3,652	3,472	-4.9
Forex gain/(loss)	-28	-33		-24	210	
Extraordinary inc/(exp)	-31	317		130	256	
Tax	463	316	-31.7	1,059	1,051	-0.7
Net Profit	1,053	1,201	14.1	2,698	2,887	7.0
Net Margin %	5.9	6.7		5.5	5.6	
Adjusted Net Profit	1,110	916	-17.5	2,574	2,463	-4.3
Adjusted Net Margin %	6.2	5.1		5.3	4.8	
EPS	8.0	0.9	12.4	2.1	2.2	5.3
Adjusted EPS	0.8	0.7	-18.7	2.0	1.9	-5.8

Emkay Research 29 January 2008 2

### Quarterly and annual results summary

Profit & Loss Account - Standalone					Balance Sheet - Standalone				
Mar ending (Rs mn)	FY07	FY08E	FY09E	FY10E	Mar ending (Rs mn)	FY07	FY08E	FY09E	FY10E
Net Sales	73,389	80,384	93,601	106,375	Share Capital	1,324	1,331	1,331	1,331
Growth %	36.8	9.5	16.4	13.6	Reserves	17,622	19,943	22,469	25,375
Operating Expenses					Misc Exp	-244	-244	-244	-244
Raw Materials	54,633	59,183	69,064	78,295	Owned Funds	18,702	21,030	23,556	26,462
% of Sales	74.4	73.6	73.8	73.6	Secured Loans	3,602	3,402	3,085	2,769
Staff Costs	4,807	6,355	7,174	8,315	Unsecured Loans	2,802	10,412	10,272	10,551
% of Sales	6.6	7.9	7.7	7.8	Loan Funds	6,404	13,814	13,358	13,320
Other Expenses	6,922	7,216	8,015	9,388	Deffered Tax Liability	1,969	1,969	1,969	1,969
% of Sales	9.4	9.0	8.6	8.8	Total	27,075	36,813	38,883	41,751
EBIDTA	7,027	7,630	9,348	10,377	Gross Fixed Assets	26,202	32,702	37,202	41,702
Growth %	30.1	8.6	22.5	11.0	Acc. Depreciation	13,132	14,953	17,111	19,530
EBIDTA %	9.6	9.5	10.0	9.8	Net Fixed Assets	13,070	17,749	20,091	22,172
Depreciation	1,506	1,821	2,158	2,419	Capital WIP	2,375	3,500	3,000	3,000
EBIT	5,521	5,809	7,190	7,958	Net Block	15,445	21,249	23,091	25,172
Other Income	743	795	840	875	Investments	2,211	2,811	3,211	3,411
Interest	318	622	668	559	Sundry Debtors	5,229	7,245	10,093	11,127
PBT	5,946	5,982	7,362	8,273	Inventory	10,703	12,165	14,165	15,762
Extraordinary inc/(exp)	99	330	0	0	Cash & Bank	4,349	4,268	1,483	1,064
Tax	1,632	1,645	2,025	2,275	Advances	6,696	7,628	8,325	9,694
Net Profit	4,413	4,667	5,338	5,998	Current Assets	26,977	31,306	34,065	37,647
Net Margin %	6.0	5.8	5.7	5.6	Liabilities	16,516	16,733	19,378	22,080
Growth %	34.8	5.8	14.4	12.4	Provisions	1,042	1,819	2,106	2,400
EPS	3.3	3.5	4.0	4.5	<b>Current Liabilities</b>	17,559	18,552	21,484	24,480
Adjusted EPS	3.3	3.3	4.0	4.5	Net Current Assets	9,419	12,753	12,581	13,168
Adjusted CEPS	4.4	4.6	5.6	6.3	Total	27,075	36,813	38,883	41,751

Source: Emkay Research

**Ratios** 

Source: Emkay Research

Cash Flow					Ratios				
Mar ending (Rs mn)	FY07	FY08E	FY09E	FY10E	Mar ending (Rs mn)	FY07	FY08E	FY09E	FY10E
Net Profit before tax	5,946	5,982	7,362	8,273	Per Share Data				
Add: Depreciation	1,506	1,821	2,158	2,419	Adj EPS	3.3	3.3	4.0	4.5
Add: Interest	318	622	668	559	Adj CEPS	4.4	4.6	5.6	6.3
Less: Other income	743	795	840	875	BVPS	14.1	15.8	17.7	19.9
(Dec)/Inc in Working capital	(372)	3,416	2,613	1,005	Valuation ratio				
Less: Tax paid	1,356	1,645	2,025	2,275	P/E	11.3	11.4	9.2	8.2
Cash from operations	5,000	2,569	4,710	7,096	Cash P/E	8.4	8.0	6.6	5.9
Capex	(6,704)	(7,625)	(4,000)	(4,500)	P/BV	2.6	2.3	2.1	1.9
Investments and others	(1,535)	(600)	(400)	(200)	EV/EBIDTA	6.9	7.3	6.2	5.6
Other income	743	795	840	875	Retun Ratios (%)				
Cash from Investing activites	(7,497)	(7,430)	(3,560)	(3,825)	AROE	26.9	23.5	23.9	24.0
Borrowings	1,332	7,627	(457)	(38)	AROCE	23.7	20.3	19.8	20.9
Interest paid	(169)	(622)	(668)	(559)	Dupont				
Dividend paid	(4,057)	(2,556)	(2,811)	(3,092)	NPM (%)	6.0	5.8	5.7	5.6
Cash from financing activites	(2,894)	4,450	(3,936)	(3,690)	Sales/TA	1.6	1.5	1.6	1.6
Cash generation during the year	(5,391)	(407)	(2,785)	(419)	TA/Equity	2.4	2.6	2.6	2.5
Opening Balance*	8,503	4,349	4,268	1,483	Other key ratios				
Closing Balance*	3,112	3,938	1,483	1,064	D/E	0.3	0.7	0.6	0.5
* Represents cash and cash equive	alents for F	Y06 and FY0	7		NWC/Sales (%)	6.9	10.6	11.9	11.4

<sup>\*</sup> Represents cash and cash equivalents for FY06 and FY07

Source: Emk ay Research

Source: Emkay Research

Emkay Research 29 January 2008 3

DISCLAIMER: This document is not for public distribution and has been furnished to you solely for your information and may not be reproduced or redistributed to any other person. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries, including the United States. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. No person associated with Emkay Share & Stock Brokers Ltd is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this document. The material is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon. Neither Emkay Share & Stock Brokers Ltd, nor any person connected with it, accepts any liability arising from the use of this document. The recipient of this material should rely on their own investigations and take their own professional advice. Opinions expressed are our other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. We and our affiliates, officers, directors, and employees world wide, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) menioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the compan

Emkay Share and Stock Brokers Ltd.,

Paragon Center, Ground Floor, C-6
Pandurang Budhkar Marg, Worli, Mumbai – 400 013. , Tel no. 66121212. Fax: 66121299

Emkay Research 29 January 2008 4